左甲状腺素/碘塞罗宁联合治疗甲减的循证应用:共识文件
美国甲状腺协会、英国甲状腺协会和欧洲甲状腺协会于2019年联合召开会议,基于12位专家报告和讨论,生成关于左甲状腺素(LT4)与碘塞罗宁(LT3)联合治疗未来临床试验设计的共识声明,34条声明中28条获至少75%同意,13条获100%同意。
要点
- 联合治疗临床试验应纳入对当前治疗不满意且LT4日剂量至少1.2 μg/kg的患者。
- LT3应每日两次给药,或优先使用缓释制剂(若可用)。
- 主要终点应使用患者报告结局(工具需具备内容效度和反应性),次要终点包括患者偏好。
主要发现
- 34条共识声明中28条获至少75%同意,13条获100%同意。
关键数值与推荐
- 研究应针对碘塞罗宁脱碘酶和甲状腺激素转运体多态性对结局的影响进行功效计算。
- 纳入对当前治疗不满意且需要至少1.2 μg/kg/天LT4的患者。
- 使用每日两次LT3或优先使用缓释制剂(若可用)。
- 主要结局使用患者报告结局(工具需具备内容效度和反应性),次要结局包括患者偏好。
- 采用随机、安慰剂对照、足够功效、双盲、平行设计。
临床怎么用
- 共识声明为未来LT4/LT3联合治疗临床试验设计提供指导,结果预期有助于患者并为临床实践指南提供信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Fourteen clinical trials have not shown a consistent benefit of combination therapy with levothyroxine (LT4) and liothyronine (LT3). Despite the publication of these trials, combination therapy is widely used and patients reporting benefit continue to generate patient and physician interest in this area. Recent scientific developments may provide insight into this inconsistency and guide future studies. Methods: The American Thyroid Association (ATA), British Thyroid Association (BTA), and European Thyroid Association (ETA) held a joint conference on November 3, 2019 (live-streamed between Chicago and London) to review new basic science and clinical evidence regarding combination therapy with presentations and input from 12 content experts. After the presentations, the material was synthesized and used to develop Summary Statements of the current state of knowledge. After review and revision of the material and Summary Statements, there was agreement that there was equipoise for a new clinical trial of combination therapy. Consensus Statements encapsulating the implications of the material discussed with respect to the design of future clinical trials of LT4/LT3 combination therapy were generated. Authors voted upon the Consensus Statements. Iterative changes were made in several rounds of voting and after comments from ATA/BTA/ETA members. Results: Of 34 Consensus Statements available for voting, 28 received at least 75% agreement, with 13 receiving 100% agreement. Those with 100% agreement included studies being powered to study the effect of deiodinase and thyroid hormone transporter polymorphisms on study outcomes, inclusion of patients dissatisfied with their current therapy and requiring at least 1.2 μg/kg of LT4 daily, use of twice daily LT3 or preferably a slow-release preparation if available, use of patient-reported outcomes as a primary outcome (measured by a tool with both relevant content validity and responsiveness) and patient preference as a secondary outcome, and utilization of a randomized placebo-controlled adequately powered double-blinded parallel design. The remaining statements are presented as potential additional considerations. Discussion: This article summarizes the areas discussed and presents Consensus Statements to guide development of future clinical trials of LT4/LT3 combination therapy. The results of such redesigned trials are expected to be of benefit to patients and of value to inform future thyroid hormone replacement clinical practice guidelines treatment recommendations.
引用
- Jonklaas J, Bianco AC, Cappola AR, et al. Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document. Thyroid. 2021. PMID: 33276704. doi:10.1089/thy.2020.0720
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。